Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A pharmaceutical suspension formulation comprising
   a. as a first active ingredient, particles of R,R-formoterol or a pharmaceutically acceptable salt thereof, said particles being suspended in the formulation,
   b. as a second active ingredient, particles of ciclesonide or a pharmaceutically acceptable salt thereof, said particles being suspended in the formulation, and
   c. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof,

   wherein said first active ingredient and said second active ingredient are the sole active ingredients in said pharmaceutical suspension formulation, and are readily dispersible, and upon redispersion do not flocculate as to prevent reproducing dosing of said first active ingredient and/or said second active ingredient.

2. (Currently amended) The pharmaceutical suspension formulation according to claim 1 comprising
   a. as a first active ingredient, particles of micronized R,R-formoterol, or a pharmaceutically acceptable salt thereof, said particles being suspended in the formulation,

b. as a second active ingredient, particles of micronized ciclesonide or a pharmaceutically acceptable salt thereof, said particles being suspended in the formulation,

c. ethanol,

d. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, and

e. optionally further comprising a surfactant,

wherein said first active ingredient and said second active ingredient are the sole active ingredients in said pharmaceutical suspension formulation, and are readily dispersible, and upon redispersion do not flocculate as to prevent reproducing dosing of said first active ingredient and/or said second active ingredient.

3. (Previously presented) The pharmaceutical suspension formulation according to claim 1 containing less than 3% by weight of ethanol.

4. (Currently amended) The pharmaceutical suspension formulation according to claim 1 comprising

a. as a first active ingredient, particles of micronized R,R-formoterol, or a pharmaceutically acceptable salt thereof, said particles being suspended in the formulation,

b. as a second active ingredient, particles of micronized ciclesonide or a pharmaceutically acceptable salt thereof, said particles being suspended in the formulation,

c. a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, and

d. further comprising a surfactant,

wherein said first active ingredient and said second active ingredient are the sole active ingredients in said pharmaceutical suspension formulation, and are readily dispersible, and upon redispersion do not flocculate as to prevent reproducing dosing of said first active ingredient and/or said second active ingredient.

5. (Cancelled)

6. (Currently amended) The pharmaceutical suspension formulation according to claim 1 which comprises R,R-formoterol fumarate dihydrate.

7. (Previously presented) The pharmaceutical suspension formulation according to claim 1 which comprises oleic acid as surfactant.

8. (Previously presented) The pharmaceutical suspension formulation according to claim 7 which comprises about 0.001 to 0.1 % (w/w) of oleic acid.

9. (Previously presented) The pharmaceutical suspension formulation according to claim 1 which comprises HFA 227 as propellant.

10. (Previously presented) The pharmaceutical suspension formulation according to claim 1 comprising disodium chromoglycate at a concentration which is not therapeutically and/or prophylactically active.

11. (Previously presented) The pharmaceutical suspension formulation according to claim 1, which is administered in a once daily dosing regimen.